Monitor Q3 2026 patient treatment volume and revenue recognition rate, the two failed batches in Q2 highlight manufacturing yield risk. The CMS NTAP designation is a positive structural catalyst for hospital adoption and Medicare patient access, but the company's cash runway (approx. 4-5 quarters at current burn) and path to profitability remain key overhangs. Watch for QTC activation pace and biopsy-to-treatment conversion rates as leading indicators of commercial trajectory.
Drugs in focus
ABEO drug pipeline →ZEVASKYN
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially launched in the U.S. (April 2025).
- Next catalyst
- None dated
What to watchZEVASKYN is already approved and generating revenue, so the binary approval catalyst is behind it. Watch quarterly commercial metrics (patient starts, revenue growth, treatment center expansion) and the CMS NTAP designation effective October 2026 for reimbursement tailwinds. The stock's ~214% implied upside to the mean analyst target reflects optimism on commercial ramp, but ongoing cash burn and EPS misses warrant caution.
Price Chart
Executive Summary
Abeona reported Q2 2026 net product revenue of $11.4M, up 31% QoQ from $8.7M in Q1 2026, driven by five patient treatments. Net loss widened to $(20.2)M ($(0.35)/share) vs $(17.1)M in Q1, primarily due to a $(7.2)M non-cash charge from the change in fair value of warrant liabilities. Cash burn continues with cash and investments declining to $146.8M from $191.4M at year-end 2025. The CMS NTAP designation for ZEVASKYN effective October 2026 is a positive catalyst for hospital adoption, but the company remains pre-profitability with no analyst consensus provided for Q2 to gauge surprise magnitude.
Key Financial Metrics
Key Facts
- Q2 2026 net product revenue $11.4M, up 31% QoQ from $8.7M in Q1 2026
- Five patients treated in Q2; three additional treatments in Q3 to-date; 12 total since launch
- Net loss $(20.2)M or $(0.35)/share vs $(17.1)M or $(0.30)/share in Q1 2026
- Cash, cash equivalents and short-term investments $146.8M as of June 30, 2026, down from $191.4M at Dec 31, 2025
- CMS granted NTAP status for ZEVASKYN effective October 1, 2026, supporting hospital adoption
- QTC network expanded to seven sites; Cincinnati Children's activated in Q3 2026
- Revenue not recognized for two patients due to low manufacturing yield or lot release failures
- R&D expenses $5.0M in Q2 vs $9.6M in Q1 (Q1 included $7.0M one-time in-licensing fee for ABO-701)
- SG&A expenses $15.8M in Q2 vs $19.5M in Q1, reflecting fewer engineering runs and training costs
Financial Impact
Q2 net product revenue $11.4M; net loss $(20.2)M; cash burn $44.6M in H1 2026
Risk Factors
- Manufacturing yield failures, two batches did not meet release specs or had low yield, preventing revenue recognition
- Cash burn rate, $44.6M consumed in H1 2026; $146.8M remaining provides limited runway without additional financing
- Commercial adoption still early, only 12 total treatments since launch; scalability of QTC network unproven
- Dependence on single product ZEVASKYN; ABO-701 still preclinical with IND filing expected H2 2027
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-037575 |
| Document: form8-k.htm | 0001493152-26-037575 |
| Document: 0001493152-26-037575-index-headers.html | 0001493152-26-037575 |
| Document: 0001493152-26-037575-index.html | 0001493152-26-037575 |
| 8-K Data (Synthetic) | 0001493152-26-037575 |
Track record
29 reports on ABEO
4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $2.59 Now $2.60 +0.39% settles Nov 18
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
- Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
- Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
- Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
- Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers